Skip to main content
SpringerLink
Log in

Age-Dependent Changes in Breast Cancer Hormone Receptors and Oxidant Stress Markers

  • Published:
Breast Cancer Research and Treatment Aims and scope Submit manuscript

Abstract

Breast cancer incidence increases with age but this relationship has not been fully explored with regard to expression of estrogen receptor (ER) and ER-inducible genes (PR, pS2, Bcl2, cathepsin D), or the age-dependence of oxidant stress markers that also affect ER-inducible gene expression. In this three-part study, we first correlated age at diagnosis with expression of breast cancer markers ER, PR, pS2, Bcl2, and cathepsin D, quantitated by enzyme immunoassays from a European collective of ∼3000 cryobanked primary breast cancers and ∼300 adjacent non-malignant breast tissues. Results were then compared with ER and PR data reported to the SEER registry for 83,541 US cancers diagnosed during 1992–1997. Lastly, a homogeneous subset of 70 ER-positive tumors preselected from the European collective was blindly analyzed for age-specific changes in the DNA-binding content of redox-sensitive transcriprtion factors, AP1 and Sp1, and the oxidant stress-activated protein kinase, phosphorylated(P)-Erk5. Increases in breast tumor ER from patients aged <30 to >80 years mirrored 10-fold lower increases in non-malignant breast tissue ER content up to age 60, rising faster thereafter and reaching a near 25-fold differential between malignant and non-malignant breast tissue by age 80. ER-inducible markers PR, pS2, Bcl2, and cathepsin D were overexpressed in tumors relative to non-malignant breast tissue but, unlike ER, did not increase with patient age. While SEER data demonstrated that the increase in US breast cancer incidence rates after age 50 is confined to ER-positive tumors in patients of all ethnic subsets, these patients also showed a striking increase in the proportion of higher-risk ER-positive/PR-negative breast cancers arising after age 50. Mechanistically essential for ER-inducible PR expression, Sp1 DNA-binding function (but not Sp1 content) was lost with age in ER-positive tumors; and this functional defect correlated with increased tumor content of the oxidant stress marker, P-Erk5. Altogether these findings support two hypotheses: (i) dysregulated ER expression underlies the age-specific increase in breast cancer incidence after age 50; and (ii) oxidative stress and loss of Sp1 DNA-binding may contribute to an increasing incidence in higher-risk ER-positive/PR-negative breast cancers with aging.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ershler WB, Longo DL: Aging and cancer: issues of basic and clinical science. J Natl Cancer Inst 89: 1489–1497, 1997

    PubMed  Google Scholar 

  2. Benz CC: Transcription factors and breast cancer. Endocrine-Related Cancer 5: 271–282, 1998

    Google Scholar 

  3. Clemons M, Goss P: Estrogens and the risk of breast cancer. N Engl J Med 344: 276–285, 2001

    PubMed  Google Scholar 

  4. Clark GM, Osborne CK, McGuire WL: Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol 2: 1102–1109, 1984

    PubMed  Google Scholar 

  5. Diab SG, Elledge RM, Clark GM: Tumor characteristics and clinical outcome of elderly women with breast cancer. J Natl Cancer Inst 92: 550–556, 2000

    PubMed  Google Scholar 

  6. Elledge RM, Fuqua SAW: Estrogen and progesterone receptors. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the Breast. 2nd edn, Lippincott Williams & Wilkins, Philadelphia (PA), 2000, pp 471–488.

    Google Scholar 

  7. Petz LN, Nardulli A: Sp1 binding sites and an estrogen response element half-site are involved in regulation of the human progesterone receptor A promoter. Mol Endocrinol 14: 972–985, 2000

    PubMed  Google Scholar 

  8. Berry M, Nunez AM, Chambon P: Estrogen-responsive element of the human pS2 gene is an imperfectly palindromic sequence. Proc Natl Acad Sci USA 86: 1218–1222, 1989

    PubMed  Google Scholar 

  9. Martin V, Ribieras S, Song-Wang XG, Lasne Y, Frappart L, Rio MC, Dante R: Involvement of DNA methylation in the control of the expression of an estrogen-induced breast cancer associated protein (pS2) in human breast cancers. J Cell Biochem 65: 95–106, 1997

    PubMed  Google Scholar 

  10. Dong L, Wang W, Wang F, Stoner M, Reed JC, Harigai M, Samudio I, Kladde MP, Vyhlidal C, Safe S: Mechanisms of transcriptional activation of bcl-2 gene expression by 17beta-estradiol in breast cancer cells. J Biol Chem 274: 32099–32107, 1999

    PubMed  Google Scholar 

  11. Krishnan V, Wang X, Safe S: Estrogen receptor-Sp1 complexes mediate estrogen-inducible cathepsin D gene expression in MCF-7 human breast cancer cells. J Biol Chem 269: 15912–15917, 1994

    PubMed  Google Scholar 

  12. Gross GE, Clark GM, Chamness GC, McGuire WL: Multiple progesterone receptor assays in human breast cancer. Cancer Res 44: 836–840, 1984

    PubMed  Google Scholar 

  13. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, Metch B, Osborne CK: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10: 1284–1291, 1992

    PubMed  Google Scholar 

  14. Elledge RM, Green S, Pugh R, Allred DC, Clark GM, Hill J, Ravdin P, Martino S, Osborne CK: Estrogen receptor (ER) and progesterone receptor (PgR), by ligand-binding assay compared with ER, PgR and pS2, by immunohistochemistry in predicting response to tamoxifen in metastatic breast cancer: a Southwest Oncology Group study. Int J Cancer 89: 111–117, 2000

    PubMed  Google Scholar 

  15. Ciocca DR, Elledge R: Molecular markers for predicting response to tamoxifen in breast cancer patients. Endocrine 13: 1–10, 2000

    PubMed  Google Scholar 

  16. Rhodes A, Jasani B, Balaton AJ, Barnes DM, Miller KD: Frequency of oestrogen and progesterone receptor positivity by immunohistochemical analysis in 7016 breast carcinomas: correlation with patient age, assay sensitivity, threshold value, and mammographic screening. J Clin Pathol 53: 688–696, 2000

    PubMed  Google Scholar 

  17. Dickson RB, Russo J: Biochemical control of breast development. In: Harris JR, Lippman ME, Morrow M, Osborne CK (eds) Diseases of the Breast. 2nd edn, Lippincott Williams & Wilkins, Philadelphia (PA), 2000, pp 15–31

    Google Scholar 

  18. Morley JE: Hormones, aging, and endocrine disorders in the elderly. In: Felig P, Baxter JD, Frohman LA (eds) Endocrinology and Metabolism. 3rd edn, McGraw-Hill, New York (NY), 1995, pp 1813–1836

    Google Scholar 

  19. Finch CE, Schneider EL: Biology of aging. In: Goldman L, Bennett JC (eds) Cecil's Textbook of Medicine. 21st edn, WB Saunders, Philadelphia (PA), 2000, pp 13–16

    Google Scholar 

  20. Issa J-P: Aging, DNA methylation and cancer. Crit Rev Oncol/Hematol 32: 31–43, 1999

    Google Scholar 

  21. Lapidus RG, Nass SJ, Davidson NE: The loss of estrogen and progesterone receptor gene expression in human breast cancer. J Mammary Gland Biol Neoplasia 3: 85–94, 1998

    PubMed  Google Scholar 

  22. Hori M, Iwasaki M, Yoshimi F, Asato Y, Itabashi M: Hyper-methylation of the estrogen receptor alpha gene is not related to lack of receptor protein in human breast cancer. Breast Cancer 6: 79–86, 1999

    PubMed  Google Scholar 

  23. Bulun SE, Zeiioun K, Sasano H, Simpson ER: Aromatase in aging women. Semin Reprod Endocrinol 17: 349–358, 1999

    PubMed  Google Scholar 

  24. van Landeghem AA, Poortman J, Nabuurs M, Thijssen JH: Endogenous concentration and subcellular distribution of estrogens in normal and malignant human breast tissue. Cancer Res 45: 2900–2906, 1985

    PubMed  Google Scholar 

  25. Yue W, Santner SJ, Masamura S, Wang JP, Demers LM, Hamilton C, Santen RJ: Determinants of tissue estradiol levels and biologic responsiveness in breast tumors. Breast Cancer Res Treat 49(suppl 1): S1-S7; discussion S33-S37, 1998

    Google Scholar 

  26. Shim WS, Conaway M, Masamura S, Yue W, Wang JP, Kmar R, Santen RJ: Estradiol hypersensitivity and mitogen-activated protein kinase expression in long-term estrogen deprived human breast cancer cells in vivo. Endocrinol 141: 396–405, 2000

    Google Scholar 

  27. Goss PE, Strasser K: Aromatase inhibitors in the treatment and prevention of breast cancer. J Clin Oncol 19: 881–894, 2001

    PubMed  Google Scholar 

  28. Jones PA, Laird PW: Cancer epigenetics comes of age. Nature Genet 21: 163–167, 1999

    PubMed  Google Scholar 

  29. Baldwin MA, Benz CC: Redox control of zinc finger proteins. Meth Enzymol 353: 54–69, 2002

    PubMed  Google Scholar 

  30. Sun Y, Oberley LW: Redox regulation of transcriptional activators. Free Radic Biol Med 21: 335–348, 1996

    PubMed  Google Scholar 

  31. Philipsen S, Suske G: A tale of three fingers: the family of mammalian Sp/XKLF transcription factors. Nucl Acids Res 27: 2991–3000, 1999

    PubMed  Google Scholar 

  32. Suske G: The Sp-family of transcription factors. Gene 238: 291–300, 1999

    PubMed  Google Scholar 

  33. Azhang J-S, Moncrieffe MC, Kaczynski J, Ellenrieder V, Prendergast FG, Urrutia R: A conserved á-helical motif mediates the interaction of Sp1-like transcriptional repressors with the corepressor mSin3A. Mol Cell Biol 21: 5041–5049, 2001

    PubMed  Google Scholar 

  34. Han L, Lin IG, Hsieh C-H: Protein binding protects sites on stable episomes and in the chromosome from de novo methylation. Mol Cell Biol 21: 3416–3424, 2001

    PubMed  Google Scholar 

  35. Ammendola R, Mesuraca M, Russo T, Cimino F: Sp1 DNA binding efficiency is highly reduced in nuclear extracts from aged rat tissues. J Biol Chem 267: 17944–17948, 1992

    PubMed  Google Scholar 

  36. Ammendola R, Mesuraca M, Russo T, Cimino F: The DNA-binding efficiency of Sp1 is affected by redox changes. Eur J Biochem 225: 483–489, 1994

    PubMed  Google Scholar 

  37. Helenius M, Hanninen M, Lehtinen SK, Salminen A: Aging-induced upregulation of nuclear binding activities of oxidative stress responsive NF-kB transcription factor in mouse cardiac muscle. J Mol Cell Cardiol 28: 487–498, 1996

    PubMed  Google Scholar 

  38. Saville B, Wormke M, Wang F, Nguyen T, Enmark E, Kuiper G, Gustafsson JA, Safe S: Ligand-, cell-, and estrogen receptor subtype (alpha/beta)-dependent activation at GC-rich (Sp1) promoter elements. J Biol Chem 275: 5379–5387, 2000

    PubMed  Google Scholar 

  39. Safe S: Transcriptional activation of genes by 17 beta-estradiol through estrogen receptor-Sp1 interactions. Vitam Horm 62: 231–252, 2001

    PubMed  Google Scholar 

  40. Abe J, Kusuhara M, Ulevitch RJ, Berk BC, Lee J-D: Big mitogen-activated protein kinase 1 (BMK1) is a redox-sensitive kinase. J Biol Chem 271: 16586–16590, 1996

    PubMed  Google Scholar 

  41. Eppenberger-Castori S, Kueng W, Benz C, Caduff R, Varga Z, Bannwart F, Fink D, Dieterich H, Hohl M, Mueller H, Paris K, Schoumacher F, Eppenberger U: Prognostic and predictive significance of ErbB2 breast tumor levels measured by enzyme immunoassay. J Clin Oncol 19: 645–656, 2001

    PubMed  Google Scholar 

  42. Eppenberger U, Kueng W, Schlaeppi J-M, Roesel JL, Benz C, Mueller H, Matter A, Zuber M, Luescher K, Litschgi M, Schmitt M, Foekens JA, Eppenberger-Castori S: Markers of tumor angiogenesis and proteolysis independently define high-and low-risk subsets of node-negative breast cancer patients. J Clin Oncol 16: 3129–3136, 1998

    PubMed  Google Scholar 

  43. Eppenberger-Castori S, Moore DH, Thor AD, Edgerton SM, Kueng W, Eppenberger U, Benz CC: Age-associated bio-marker profiles of human breast cancer. Int J Biochem Cell Biol 34: 1318–1330, 2002

    PubMed  Google Scholar 

  44. Surveillance, Epidemiology, and End Results (SEER) Program: SEER Cancer Incidence Public-Use Database, 1973–1997, August 1999 Submission. Cancer Statistics Branch, National Cancer Institute. Bethesda (MD), Issued April 2000

  45. Liang X, Lu B, Scott GK, Chang C-H, Baldwin MA, Benz CC: Oxidant stress impaired DNA-binding of estrogen receptor from human breast cancer. Mol Cell Endocrinol 146: 151–161, 1998

    PubMed  Google Scholar 

  46. Johnston SRD, Lu B, Scott GK, Kushner PJ, Smith IE, Dowsett M, Benz CC: Increased activator protein-1 DNA binding and c-Jun NH2-terminal kinase activity in human breast tumors with acquired tamoxifen resistance. Clin Cancer Res 5: 251–256, 1999

    PubMed  Google Scholar 

  47. Briggs MR, Kadonaga JT, Bell SP, Tjian R: Purification and biochemical characterization of the promoter-specific transcription factor, Sp1. Science 234: 47–52, 1986

    PubMed  Google Scholar 

  48. Kato Y, Tapping RI, Huang S, Watson MH, Ulevitch RJ, Lee J-D: Bmk1/Erk5 is required for cell proliferation induced by epidermal growth factor. Nature 395: 713–716, 1998

    PubMed  Google Scholar 

  49. Fienberg SE: The Analysis of Cross-Classified Categorical Data. 2nd edn, The MIT Press, Cambridge, MA, 1983

    Google Scholar 

  50. McGuire WL: Steroid receptors in human breast cancer treatment strategy. Recent Prog Horm Res 36: 135–156, 1980

    PubMed  Google Scholar 

  51. Yasui Y, Potter JD: The shape of age-incidence curves of female breast cancer by hormone-receptor status. Cancer Causes Cont 10: 431–437, 1999

    Google Scholar 

  52. Bernstein L: The epidemiology of breast cancer. Women Cancer 1: 7–13, 1998

    Google Scholar 

  53. Ravdin PM, Green S, Dorr TM, McGuire WL, Fabian C, Pugh RP, Carter RD, Rivkin SE, Borst JR, Belt RJ, Metch B, Osborne CK: Prognostic significance of progesterone receptor levels in estrogen receptor-positive patients with metastatic breast cancer treated with tamoxifen: results of a prospective Southwest Oncology Group study. J Clin Oncol 10: 1284–1291, 1992

    PubMed  Google Scholar 

  54. Harvey JM, Clark GM, Osborne CK, Allred DC: Estrogen receptor status by immunohistochemistry is superior to the ligand-binding assay for predicting response to adjuvant en-docrine therapy in breast cancer. J Clin Oncol 17: 1474–1481, 1999

    PubMed  Google Scholar 

  55. Sorlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, Hastie T, Eisen MB, van de Rijn M, Jeffrey SS, Thorsen T, Quist H, Matese JC, Brown PO, Botstein D, Lonning PE, Borresen-Dale A-L: Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA 98: 10869–10874, 2001

    PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Cancer Center, University of California, San Francisco, CA, USA

    Judy Quong, Dan Moore III & Christopher C. Benz

  2. Stiftung Tumorbank Basel and Department of Research, University Clinics, Basel, Switzerland

    Serenella Eppenberger-Castori, Willy Kueng & Urs Eppenberger

  3. Geraldine Brush Cancer Research Institute, California Pacific Medical Center, San Francisco, CA, USA

    Dan Moore III

  4. Buck Institute for Age Research, Novato, CA, USA

    Gary K. Scott & Christopher C. Benz

  5. National Cancer Institute, Bethesda, MD, USA

    Michael J. Birrer

Authors
  1. Judy Quong
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Serenella Eppenberger-Castori
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Dan Moore III
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Gary K. Scott
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Michael J. Birrer
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Willy Kueng
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. Urs Eppenberger
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. Christopher C. Benz
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Quong, J., Eppenberger-Castori, S., Moore, D. et al. Age-Dependent Changes in Breast Cancer Hormone Receptors and Oxidant Stress Markers. Breast Cancer Res Treat 76, 221–236 (2002). https://doi.org/10.1023/A:1020886801674

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1020886801674

Search

Navigation